Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 3,592,118 shares, a growth of 20.9% from the February 26th total of 2,971,195 shares. Approximately 19.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 713,792 shares, the short-interest ratio is presently 5.0 days.

Karyopharm Therapeutics Stock Up 5.1%

Shares of NASDAQ:KPTI traded up $0.27 during midday trading on Tuesday, reaching $5.57. The company’s stock had a trading volume of 505,419 shares, compared to its average volume of 995,484. The firm has a market cap of $102.15 million, a price-to-earnings ratio of -0.34 and a beta of 0.13. The business has a 50 day moving average price of $7.70 and a 200 day moving average price of $6.81. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The business had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. Sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds have recently modified their holdings of KPTI. Baird Financial Group Inc. acquired a new position in Karyopharm Therapeutics during the second quarter worth approximately $45,000. XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $56,000. Corient Private Wealth LLC purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $74,000. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $95,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth $135,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KPTI. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. HC Wainwright cut their target price on shares of Karyopharm Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They set an “overweight” rating on the stock. Robert W. Baird lowered their price target on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, March 25th. Finally, Rodman & Renshaw raised shares of Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $14.29.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.